Azmasol HFA Refill100 mcg

Azmasol HFA Refill is a short-acting beta-2 adrenergic agonist (SABA) bronchodilator used for the relief and prevention of bronchospasm in reversible obstructive airway disease.

Established / FDA-Approved Uses

• Relief of acute bronchospasm (rescue/reliever therapy) in patients with asthma and chronic obstructive pulmonary disease (COPD), approved for patients 4 years of age and older for the inhaler.
• Prevention of exercise-induced bronchospasm when taken shortly before exertion.

Guideline-Supported Uses

• As the preferred as-needed reliever medication in stepwise asthma management guidelines (e.g. GINA), used alongside, not instead of, regular anti-inflammatory (inhaled corticosteroid) therapy.
• Nebulized Azmasol HFA Refill for symptomatic relief of bronchospasm during acute asthma or COPD exacerbations, including in hospital and emergency settings.

Adjunct / Combination Therapy Uses

• Nebulized Azmasol HFA Refill, often combined with ipratropium bromide, as adjunct bronchodilator therapy in acute severe asthma and COPD exacerbations.
• As adjunct therapy (with intravenous dextrose/insulin and other standard measures), under specialist supervision, in the emergency management of hyperkalaemia.

Off-Label Use

• Azmasol HFA Refill tablets/syrup are used off-label as a tocolytic-adjacent bronchodilator in some regions, and nebulized Azmasol HFA Refill has been trialed in bronchiolitis; however, evidence does not support routine use in bronchiolitis and this is not a recommended standard use.

Azmasol HFA Refill is a bronchodilator only; it does not treat underlying airway inflammation and is not a substitute for inhaled corticosteroids in persistent asthma.

Salbutamol is available in Bangladesh in several formulations: tablets (2 mg and 4 mg, as salbutamol sulfate), oral syrup (2 mg/5 mL), pressurized metered-dose inhaler (100 mcg per actuation), dry powder inhalation capsules (200 mcg), nebulizer (respirator) solution (5 mg/mL, and unit-dose respules such as 2.5 mg/2.5 mL), and injection for intravenous infusion (500 mcg/mL), each containing salbutamol (as salbutamol sulfate) as the active ingredient along with standard pharmaceutical excipients.

Azmasol HFA Refill (also known internationally as albuterol) is a short-acting, selective beta-2 adrenergic receptor agonist bronchodilator. It is one of the most widely used "reliever" medicines for asthma and COPD worldwide, valued for its rapid onset of bronchodilation, typically within minutes of inhalation, and its relatively favorable safety profile at recommended doses. Azmasol HFA Refill is available as inhalers, nebulizer solutions, oral tablets/syrup, and injectable formulations to suit different clinical situations, from routine as-needed symptom relief to management of acute severe bronchospasm.

Azmasol HFA Refill belongs to the class of short-acting beta-2 adrenergic agonists (SABA), a subgroup of bronchodilator drugs used for the rapid relief of bronchospasm in obstructive airway disease.

Salbutamol selectively stimulates beta-2 adrenergic receptors located on bronchial smooth muscle. Receptor activation stimulates adenylate cyclase, raising intracellular cyclic AMP (cAMP) levels, which relaxes bronchial smooth muscle from the trachea to the terminal bronchioles and inhibits release of bronchoconstricting mediators (e.g. histamine) from mast cells. At therapeutic doses, Salbutamol has relatively little effect on beta-1 (cardiac) receptors, though some cardiac stimulation can occur, especially at higher doses.

Pharmacokinetics

• Onset of action (inhaled): Within 5-15 minutes
• Peak effect: Approximately 1-2 hours
• Duration of action: Approximately 3-6 hours
• Metabolism: Primarily hepatic, via sulfation to an inactive metabolite
• Elimination: Predominantly renal, as both unchanged drug and metabolite

Inhaler: Shake well before use, breathe out fully, place the mouthpiece in the mouth and close lips around it, then press the canister while inhaling slowly and deeply; hold breath for about 10 seconds before exhaling. Wait about 1 minute between puffs if a second dose is needed. Nebulizer solution: Dilute as directed and administer via a jet nebulizer with adequate airflow over approximately 5-15 minutes until the chamber is empty; do not mix with other drugs in the nebulizer unless directed by a physician. Tablets/syrup: May be taken with or without food, at evenly spaced intervals. Injection: For hospital administration only, by slow intravenous injection or infusion under medical supervision. Azmasol HFA Refill inhaled or nebulized forms are for oral inhalation only and must never be injected; injectable Azmasol HFA Refill must never be given by mouth.

Azmasol HFA Refill has clinically significant interactions with the following:

• Beta-blockers (especially non-selective, e.g. propranolol): May block the bronchodilator effect of Azmasol HFA Refill and can produce severe bronchospasm in patients with asthma; if a beta-blocker is required, a cardioselective agent should be used with caution.
• Non-potassium-sparing diuretics (loop or thiazide): May worsen Azmasol HFA Refill-induced hypokalemia; monitor serum potassium, especially at high doses.
• Other sympathomimetic agents (e.g. epinephrine, other bronchodilators): Concomitant use may increase the risk of adverse cardiovascular effects.
• Digoxin: Azmasol HFA Refill may lower serum digoxin concentrations; monitoring of digoxin levels is advised.
• Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: May potentiate the cardiovascular effects of Azmasol HFA Refill; use with extreme caution, including within 2 weeks of MAOI discontinuation.
• Corticosteroids: Concomitant use, particularly with high-dose Azmasol HFA Refill, may increase the risk of hypokalemia; monitor potassium in at-risk patients.

The most commonly reported side effects of Azmasol HFA Refill are dose-related and include:

• Fine tremor (especially of the hands), nervousness, and headache
• Palpitations and tachycardia
• Muscle cramps
• Throat irritation, cough, and dry mouth (with inhaled forms)
• Dizziness and restlessness

Less commonly, Azmasol HFA Refill can cause hypokalemia (particularly with high or frequent doses), hyperglycemia, and peripheral vasodilation. Rarely, it can cause a life-threatening paradoxical bronchospasm or hypersensitivity reactions (see Precautions and Warnings and Contraindications). Seek prompt medical attention for chest pain, irregular heartbeat, or worsening breathing difficulty after use.

Pregnancy: There are no adequate, well-controlled studies of Azmasol HFA Refill in pregnant women; animal studies have shown some adverse effects at high doses. However, poorly controlled asthma during pregnancy poses a greater risk to both mother and fetus than appropriately used reliever therapy, so inhaled Azmasol HFA Refill is generally continued as needed for asthma control in pregnancy. Azmasol HFA Refill should be used in pregnancy only if the potential benefit justifies the potential risk, and only under medical supervision; because of its tocolytic (uterine-relaxant) effect, intravenous or high-dose use near term/during labor should be avoided unless clearly needed.

Lactation: It is not known whether clinically significant amounts of Azmasol HFA Refill are excreted in human breast milk; plasma levels after inhaled use are low. A physician should be consulted to weigh the benefits of treatment against any potential risk to the infant before use while breastfeeding.

Paradoxical bronchospasm: Inhaled Azmasol HFA Refill can, rarely, cause a life-threatening paradoxical bronchospasm; discontinue immediately if this occurs and seek alternative therapy.

Deteriorating asthma/COPD control: Increasing or unusually frequent use of Azmasol HFA Refill for symptom relief signals worsening disease control and warrants prompt medical reassessment of the overall treatment plan; it is not a substitute for regular anti-inflammatory therapy (e.g. inhaled corticosteroids).

Cardiovascular effects: Use with caution in patients with cardiovascular disorders (especially coronary insufficiency, arrhythmias, and hypertension), as beta-agonists can affect heart rate, rhythm, and blood pressure.

Hypokalemia: High or frequent doses of Azmasol HFA Refill may cause clinically significant hypokalemia, which may be worsened by concomitant use of diuretics or corticosteroids (see Interactions); monitor potassium in at-risk patients.

Use with caution in patients with hyperthyroidism, diabetes mellitus, or convulsive disorders. Fatalities have been reported in association with excessive use of inhaled short-acting beta-agonists; do not exceed the recommended dose or frequency of Azmasol HFA Refill.

Overdose of Azmasol HFA Refill may cause exaggerated beta-adrenergic effects, including marked tachycardia and arrhythmias, hypertension or hypotension, angina, tremor, nervousness, headache, muscle cramps, dry mouth, seizures, hypokalemia, hyperglycemia, and lactic acidosis. If an overdose of Azmasol HFA Refill is suspected, seek immediate medical attention or contact a poison control center right away; treatment is generally supportive and includes discontinuation of the drug, cardiac monitoring, and correction of electrolyte disturbances, with a cardioselective beta-blocker considered only with extreme caution due to the risk of inducing bronchospasm.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not refrigerate or freeze the inhaler canister; avoid exposing it to heat, and do not puncture, break, or burn the canister even when apparently empty. Protect nebulizer ampoules/respules from light and use promptly once opened, discarding any unused solution as directed.

Pediatric Use

The Azmasol HFA Refill inhaler is approved for children 4 years of age and older; oral tablets/syrup and nebulizer solution are used from about 2 years of age (weight/age-based dosing) under medical supervision. Safety and efficacy in infants and neonates are not well established outside specialist medical care.

Geriatric Use

Elderly patients may be more sensitive to the cardiovascular effects of Azmasol HFA Refill; use with caution, particularly in those with pre-existing cardiovascular disease.

Renal/Hepatic Impairment

No specific dose adjustment for renal or hepatic impairment is well established for Azmasol HFA Refill; use with caution and clinical monitoring, particularly with oral or injectable forms.

Pregnancy and Lactation

See Pregnancy and Lactation for detailed guidance on the use of Azmasol HFA Refill in these populations.

Azmasol HFA Refill is typically used as needed for relief of acute symptoms, or shortly before exercise for prevention of exercise-induced bronchospasm; it is not intended for regular, scheduled long-term use as monotherapy. If daily or near-daily use of Azmasol HFA Refill is required to control symptoms, the overall asthma or COPD treatment plan should be reviewed by a physician, as this often indicates a need for additional maintenance (anti-inflammatory) therapy.

Short-acting beta-2 adrenergic agonist (SABA); sympathomimetic bronchodilator.

Salbutamol selectively stimulates beta-2 adrenergic receptors in bronchial smooth muscle. This activates adenylate cyclase, raising intracellular cyclic AMP levels, which relaxes bronchial smooth muscle and produces bronchodilation, while also inhibiting the release of bronchoconstricting mediators from mast cells. Its relative selectivity for beta-2 over beta-1 receptors gives it bronchodilator activity with comparatively less cardiac stimulation than non-selective sympathomimetics, though cardiac effects can still occur, particularly at higher doses.

C

Azmasol HFA Refill inhaler is indicated for the treatment and prevention of bronchospasm in children 4 years of age and older with reversible obstructive airway disease. Nebulizer solution and oral tablets/syrup are used from approximately 2 years of age, with dosing individualized by age and weight, under medical supervision. Use of Azmasol HFA Refill in infants and neonates should be limited to specialist medical settings, as safety and efficacy in this age group have not been well established. Children using Azmasol HFA Refill frequently should be reassessed for overall asthma control.